Cannabis has been threaded through American popular music for as long as American popular music has existed. Louis Armstrong wrote about it. Bob Dylan reportedly turned the Beatles onto it. Willie Nelson built half his persona around it. Cypress Hill, Snoop Dogg, Wiz Khalifa, and a long lineage of hip-hop artists made it a foundational cultural reference point. For most of that history, the relationship was about identity. Cannabis was countercultural, recreational, and, in plenty of cases, a stylistic position as much as a personal habit.
Over the last fifteen years, something quieter has been happening underneath that more familiar story. Working musicians, especially those in the touring middle class that publications like this one tend to cover, have started talking about cannabis differently. Not as a lifestyle marker. Not as a counterculture flag. As a tool for managing the actual physical and mental wear of a job that most listeners never see the back end of.
The Etheridge Story
The clearest pivot point in the public conversation came from Melissa Etheridge. In October 2004, twelve years after winning her first Grammy and eight months after releasing her eighth studio album, she was diagnosed with breast cancer. Her treatment was dose-dense chemotherapy, the harsher protocol generally reserved for patients who can take time off work. Her friend David Crosby, who had his own complicated medical history, suggested she try cannabis to manage the side effects. She did.
In a 2005 Dateline interview and a 2013 op-ed for CNN, Etheridge talked openly about what that experience had been. The cannabis worked. Her doctors, she said, were not surprised, and several actively endorsed it. The experience changed her relationship to the plant entirely. She has spent the two decades since as one of the music industry’s most public medical cannabis advocates, has launched (and fought legal battles over) a cannabis brand, and after losing her son Beckett to opioid-related causes in 2020, founded the Etheridge Foundation to support research into new treatments for opioid use disorder.
The Etheridge story matters because it cut against the existing template. She was not a counterculture artist making a counterculture statement. She was an Academy Award winner from Leavenworth, Kansas, talking about cannabis the way other patients talk about a prescription. That reframing has shown up in dozens of artist interviews since, with varying degrees of public attention.
The Petty Inflection Point
The harder, less optimistic chapter of this story is Tom Petty.
Petty toured 53 dates of the Heartbreakers’ 40th anniversary tour in 2017 with a fractured hip. The injury worsened across the tour. On the day he died, October 2, 2017, his medical team informed him that the fracture had become a full break. The accidental overdose that killed him a few hours later involved fentanyl, oxycodone, alprazolam, temazepam, and citalopram, a stack of legitimately prescribed medications that he had been taking to keep working through pain that had become unbearable.
His family’s public statement, released alongside the coroner’s findings in January 2018, made the policy implication explicit. “As a family we recognize this report may spark a further discussion on the opioid crisis,” they wrote, “and we feel that is a healthy and necessary discussion and we hope in some way this report can save lives. Many people who overdose begin with a legitimate injury or simply do not understand the potency and deadly nature of these medications.”
The Petty story is not about cannabis. It is about what the existing pharmaceutical pain management toolkit looks like when applied to a working musician trying to honor commitments to a touring schedule and to fans. But it is impossible to read the family’s statement and not notice what is missing from the conversation: alternatives. The discussion about non-opioid pain management has been one of the quieter but more consistent threads running through artist interviews ever since.
What the Road Actually Does
Touring is harder on the body than the public image of it suggests. Drummers and percussionists develop chronic shoulder, wrist, and back issues. Guitarists and bassists deal with cervical and lumbar strain from carrying instruments and from the postural toll of long sets. Vocalists work through reflux and vocal cord injuries. Sound engineers and crew take on hearing damage that catches up with them in their forties and fifties. The financial precarity of independent touring, which has gotten worse, not better, since streaming reordered the industry’s economics, layers stress onto an already strained system.
State medical cannabis programs recognize many of the conditions this lifestyle generates. Chronic pain, severe muscle spasms, neuropathic pain, severe anxiety, PTSD (especially relevant to veterans in the music industry, of which there are more than most listeners realize), and in several states fibromyalgia and migraines, are all covered. The 40 states with comprehensive medical cannabis programs have largely converged on a list of common qualifying conditions for medical cannabis that maps closely onto the chronic conditions that working musicians develop and manage over time.
Why Telehealth Made the Difference
The single biggest practical change in the last five years has been the expansion of telehealth certification. For most of the medical cannabis era, getting certified meant finding a participating physician in your home state, scheduling an in-person visit, and going through a multi-week process before you could legally purchase from a dispensary. For working musicians, who often spend more nights of the year in hotels than in their own apartments, that process was hard to fit into a touring calendar.
That changed gradually starting around 2020 and has accelerated since. Most states now allow at least the renewal portion of the certification by video, and several allow the entire process to take place remotely. Telehealth platforms now offer online medical cannabis evaluations that can be conducted from a tour bus, a hotel room, or a green room before a load-in, with the certification submitted to the state’s medical marijuana registry the same day. For an artist on a six-week run, that flexibility is the difference between actually getting certified and putting it off indefinitely.
What the Pivot Means
The cultural conversation around music and cannabis is still mostly stuck in the older frame. Cannabis-themed festivals, brand collaborations between artists and dispensary chains, and the long tail of stoner-image marketing continue, and they will probably continue. None of that is going away.
But the parallel conversation, the quieter one, is real and growing. Artists in their forties, fifties, and sixties are talking publicly about using medical cannabis the way previous generations talked about ibuprofen or wine. The framing is functional rather than performative. It is about managing chronic pain so you can keep playing, managing performance anxiety so you can keep working, managing sleep so the next show is not worse than the last one. It does not make for great album-cover iconography, and it is unlikely to generate a generation-defining hip-hop anthology. But it is changing how a lot of working musicians actually live their lives.
The cultural identity story has had its moment, and it will keep having moments. The wellness story is less photogenic but, judging by the way artists are increasingly talking about it, more durable. Both are legitimate. The shift between them is one of the more interesting underreported things happening in the music industry right now.
